Corinne Epperly
Directeur/Bestuurslid bij IN8BIO, INC.
Vermogen: 85 246 $ op 30-04-2024
Profiel
Corinne D.
Epperly is a professional with experience in various firms.
She has worked as a Director at IN8bio, Inc. since 2023.
Previously, she worked as an Independent Director at AVEO Pharmaceuticals, Inc. from 2021 to 2023, a Research Analyst at Goldman Sachs International in 2010, the Chief Operating Officer at Vascular Biogenics Ltd.
from 2017 to 2018, the Senior Vice President-Strategy & Operations at Iovance Biotherapeutics, Inc. from 2019 to 2020, and the Chief Operating Officer at Cargo Therapeutics, Inc. from 2021 to 2023.
Dr. Epperly received her undergraduate degree from the University of Virginia and her graduate and doctorate degrees from The University of North Carolina at Charlotte.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IN8BIO, INC.
0.19% | 17-04-2024 | 81 967 ( 0.19% ) | 85 246 $ | 30-04-2024 |
Actieve functies van Corinne Epperly
| Bedrijven | Functie | Begin |
|---|---|---|
| IN8BIO, INC. | Directeur/Bestuurslid | 07-12-2023 |
Eerdere bekende functies van Corinne Epperly
| Bedrijven | Functie | Einde |
|---|---|---|
| CARGO THERAPEUTICS, INC. | Operationeel Directeur | 01-12-2023 |
| AVEO PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 19-01-2023 |
| IOVANCE BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 01-01-2020 |
| NOTABLE LABS, LTD. | Operationeel Directeur | 01-01-2018 |
Goldman Sachs International
 Goldman Sachs International Financial ConglomeratesFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Analyst-Equity | 01-10-2010 |
Opleiding van Corinne Epperly
| The University of North Carolina at Charlotte | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| CARGO THERAPEUTICS, INC. | Health Technology |
| IN8BIO, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
Goldman Sachs International
Goldman Sachs International Financial ConglomeratesFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Finance |
